Expression of type 5 somatostatin receptor in TSH-secreting pituitary adenomas: A possible marker for predicting longterm response to octreotide therapy

Endocrine Journal

Volumn 54, Issue 1, 2007, Pages 133-138

  Yoshihara, Ai ^a   Isozaki, Osamu ^a   Hizuka, Naomi ^a   Nozoe, Yasuko ^a   Harada, Chie ^a   Ono, Masami ^a   Kawamata, Takakazu ^a   Kubo, Osami ^a   Hori, Tomokatsu ^a   Takano, Kazue ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Octreotide; Somatostatin receptor; TSHoma

Indexed keywords

OCTREOTIDE; SOMATOSTATIN RECEPTOR 5; THYROTROPIN; TUMOR MARKER;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOPHYSIS ADENOMA; MALE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURGICAL TECHNIQUE; TREATMENT OUTCOME;

ADENOMA; ANTINEOPLASTIC AGENTS, HORMONAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; OCTREOTIDE; PITUITARY NEOPLASMS; PROGNOSIS; PROTEIN ISOFORMS; RECEPTORS, SOMATOSTATIN; THYROTROPIN; TIME; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 33947605750     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.K06-133     Document Type: Article

References (32)

1. Beck-Peccoz P, Brucker-Davis F, Persani L, Smallridge RC, Weintraub BD (1996) Thyrotropin-secreting pituitary tumors. Endocr Rev 17: 610-638.
2. Mindermann T, Wilson CB (1993) Thyrotropin-producing pituitary adenomas. J Neurosurg 79: 521-527.
3. Saeger W, Ludecke DK (1982) Pituitary adenomas with hyperfunction of TSH: frequency, histological classification, immunocytochemistry and ultrastructure. Virchows Arch A Pathol Anat Histol 394: 255-267.
4. Weintraub BD, Gershengorn MC, Kourides IA (1981) Inappropriate secretion of thyroid-stimulating hormone. Ann Intern Med 95: 339-351.
5. Beckers A, Abs R, Mahler C, Vandalem JL, Pirens G, Hennen G, Stevenaert A (1991) Thyrotropin-secreting pituitary adenomas: report of seven cases. J Clin Endocrinol Metab 72: 477-483.
6. Chanson P, Weintraub BD, Harris AG (1993) Octreotide therapy for thyroid-stimulating hormone-secreting pituitary adenomas: a follow-up of 52 patients. Ann Intern Med 119: 236-240.
7. Beck-Peccoz P, Mariotti S, Guillausseau PJ, Medri G, Piscitelli G, Bertoli A, Barbarino A, Rondena M, Chanson P, Pinchera A (1989) Treatment of hyperthyroidism due to inappropriate secretion of thyrotropin with the somatostatin analog SMS 201-995. J Clin Endocrinol Metab 68: 208-214.
8. Caron P, Arlot S, Bauters C, Chanson P, Kuhn JM, Pugeat M, Marechaud R, Teutsch C, Vidal E, Sassano P (2001) Efficacy of the long-acting octreotide formulation (octreotide-LAR) in patients with thyrotropin-secreting pituitary adenomas. J Clin Endocrinol Metab 86: 2849-2853.
9. Chanson P, Warnet A (1992) Treatment of thyroid-stimulating hormone-secreting adenomas with octreotide. Metabolism 41(9 Suppl 2): 62-65.
10. Comi RJ, Gesundheit N, Murray L, Gorden P, Weintraub BD (1987) Response of thyrotropin-secreting pituitary adenomas to a long-acting somatostatin analogue. N Engl J Med 317: 12-17.
11. Gancel A, Vuillermet P, Legrand A, Catus F, Thomas F, Kuhn JM (1994) Effects of a slow-release formulation of the new somatostatin analogue lanreotide in TSH-secreting pituitary adenomas. Clin Endocrinol (Oxf) 40: 421-428.
12. Iglesias P, Diez JJ (1998) Long-term preoperative management of thyrotropin-secreting pituitary adenoma with octreotide. J Endocrinol Invest 21: 775-778.
13. Shimatsu A, Murabe H, Kamoi K, Suzuki Y, Nakao K (1999) Treatment of thyrotropin-secreting pituitary adenomas with octreotide. Endocr J 46: 113-123.
14. Isozaki O, Tsushima T, Nozoe Y, Miyakawa M, Takano K (2004) Leptin regulation of the thyroids: negative regulation on thyroid hormone levels in euthyroid subjects and inhibitory effects on iodide uptake and Na/I symporter mRNA expression in rat FRTL-5 cells. Endocr J 51: 415-423.
15. Ferone D, Pivonello R, Van Hagen PM, Dalm VA, Lichtenauer-Kaligis EG, Waaijers M, Van Koetsveld PM, Mooy DM, Colao A, Minuto F, Lamberts SW, Hofland LJ (2002) Quantitative and functional expression of somatostatin receptor subtypes in human thymocytes. Am J Physiol Endocrinol Metab 283: 1056-1066.
16. Ferone D, van Hagen PM, van Koetsveld PM, Zuijderwijk J, Mooy DM, Lichtenauer-Kaligis EG, Colao A, Bogers AJ, Lombardi G, Lamberts SW, Hofland LJ (1999) In vitro characterization of somatostatin receptors in the human thymus and effects of somatostatin and octreotide on cultured thymic epithelial cells. Endocrinology 140: 373-380.
17. Wemeau JL, Dewailly D, Leroy R, D'Herbomez M, Mazzuca M, Decoulx M, Jaquet P (1988) Long term treatment with a somatostatin analog SMS 201-995 in a patient with a thyrotropin and growth hormone-secreting pituitary adenoma. J Clin Endocrinol Metab 66: 636-639.
18. Levy A, Eckland DJA, Gurney AM (1989) Somatostatin and thyrotropinreleasing hormone response and receptor status of a thyrotropin-secreting pituitary adenoma: clinical and in-vitro studies. J Neuroendocrinol 1: 321-326.
19. Polak M, Bertherat K, Li JY (1991) A human TSHsecreting adenoma: endocrine biochemical and morphological studies: evidence of somatostatin receptors by using quantitative autoradiography. Clinical and biological improvement by SMS 201-995 treatment. Acta Endocrinol (Copenh) 124: 479-486.
20. Bertherat J, Brue T, Enjalbert A, Gunz G, Rasolonjanahary R, Warnet A, Jaquet P, Epelbaum J (1992) Somatostatin receptors on thyrotropin-secreting pituitary adenomas: comparison with the inhibitory effects of octreotide upon in vivo and in vitro hormonal secretion. J Clin Endocrinol Metab 75: 540-546.
21. Losa M, Magnani P, Mortini P, Persani L, Acerno S, Giugni E, Songini C, Fazio F, Beck-Peccoz P, Giovanelli M (1997) Indium-111 pentetreotide single-photon emission tomography in patients with TSH-secreting pituitary adenomas: correlation with the effect of a single administration of octreotide on serum TSH levels. Eur J Nucl Med 24: 728-731.
22. Kuhn JM, Arlot S, Lefebvre H, Caron P, Cortet-Rudelli C, Archambaud F, Chanson P, Tabarin A, Goth MI, Blumberg J, Catus F, Ispas S, Beck-Peccoz P (2000) Evaluation of the treatment of thyrotropin-secreting pituitary adenomas with a slow release formulation of the somatostatin analog lanreotide. J Clin Endocrinol Metab 85: 1487-1491.
23. Hofland LJ, Lamberts SW (2003) The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev 24: 28-47.
24. Shimon I, Taylor JE, Dong JZ, Bitonte RA, Kim S, Morgan B, Coy DH, Culler MD, Melmed S (1997) Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation. J Clin Invest 99: 789-798.
25. Panetta R, Patel YC (1995) Expression of mRNA for all five human somatostatin receptors (hSSTR1-5) in pituitary tumors. Life Sci 56: 333-342.
26. Schaer JC, Waser B, Mengod G, Reubi JC (1997) Somatostatin receptor subtypes sst1, sst2, sst3 and sst5 expression in human pituitary, gastroentero-pancreatic and mammary tumors: comparison of mRNA analysis with receptor autoradiography. Int J Cancer 70: 530-537.
27. Saveanu A, Gunz G, Dufour H, Caron P, Fina F, Ouafik L, Culler MD, Moreau JP, Enjalbert A, Jaquet P (2001) Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas. J Clin Endocrinol Metab 86: 140-145.
28. Reubi JC, Landolt AM (1989) The growth hormone responses to octreotide in acromegaly correlate with adenoma somatostatin receptor status. J Clin Endocrinol Metab 68: 844-850.
29. Barlier A, Pellegrini-Bouiller I, Gunz G, Zamora AJ, Jaquet F, Enjalbert A (1999) Impact of gsp oncogene on the expression of genes coding for Gsalpha, Pit-1, Gi2alpha, and somatostatin receptor 2 in human somatotroph adenomas: involvement in octreotide sensitivity. J Clin Endocrinol Metab 84: 2759-2765.
30. Jaquet P, Saveanu A, Gunz G, Fina F, Zamora AJ, Grino M, Culler MD, Moreau JP, Enjalbert A, Ouafik LH (2000) Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes. J Clin Endocrinol Metab 85: 781-792.
31. Danila DC, Haidar JN, Zhang X, Katznelson L, Culler MD, Klibanski A (2001) Somatostatin receptor-specific analogs: effects on cell proliferation and growth hormone secretion in human somatotroph tumors. J Clin Endocrinol Metab 86: 2976-2981.
32. Ballare E, Persani L, Lania AG, Filopanti M, Giammona E, Corbetta S, Mantovani S, Arosio M, Beck-Peccoz P, Faglia G, Spada A (2001) Mutation of somatostatin receptor type 5 in an acromegalic patient resistant to somatostatin analog treatment. J Clin Endocrinol Metab 86: 3809-3814.